Detect decreased GFR with SDMA before the majority of kidney function is lost
Historically, estimation of kidney function has depended on various methods such as glomerular filtration rate (GFR), BUN and creatinine. Standard serum biomarkers are relatively insensitive and increase only when ~75%1 of kidney function is compromised. SDMA can detect loss of kidney function earlier than creatinine and BUN biomarkers.
SDMA shows more sensitivity and reliability
Symmetric dimethylarginine (SDMA) is produced by all nucleated cells and is cleared almost exclusively by renal excretion. Standard serum biomarkers such as creatinine and BUN are affected by extrarenal factors including body mass and diet, making these biomarkers less sensitive and less reliable.
LC-MS technology leads the way
IDEXX SDMA®, a high throughput assay, has been validated in dogs, cats, horses and rats through a comparison to the LC-MS. All species validations utilize LC-MS (other species are currently in process).
|Assay||Species||Platform||Sample Type||Sample Volume|
|SDMA||Cat||Beckman||Serum, Plasma||80 µL|
|SDMA||Dog||Beckman||Serum, Plasma||80 µL|
1 Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of
symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney
disease. J Vet Intern Med. 2016;30(3):794–802